What is KI1106 4g, QD used for?

KI1106 4g, QD is indicated for Relapsed or refractory multiple myeloma.

Who makes KI1106 4g, QD?

KI1106 4g, QD is developed by Kuhnil Pharmaceutical Co., Ltd..

What are the side effects of KI1106 4g, QD?

Common side effects include Fatigue, Nausea, Diarrhea, Vomiting, Anemia, Thrombocytopenia.

Last reviewed 2026-04-23 · How we verify

KI1106 4g, QD

Kuhnil Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

KI1106 is a small molecule targeting the CD47/SIRPα axis.

KI1106 is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.

At a glance

Generic name	KI1106 4g, QD
Sponsor	Kuhnil Pharmaceutical Co., Ltd.
Drug class	CD47/SIRPα inhibitor
Target	CD47/SIRPα axis
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

KI1106 works by blocking the interaction between CD47 and SIRPα, which is involved in immune evasion by cancer cells. This blockade leads to the activation of macrophages and enhanced anti-tumor immune responses.

Approved indications

Relapsed or refractory multiple myeloma

Common side effects

Fatigue
Nausea
Diarrhea
Vomiting
Anemia
Thrombocytopenia
Neutropenia
Leukopenia
Anorexia
Weight loss

Key clinical trials

Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KI1106 4g, QD CI brief — competitive landscape report
KI1106 4g, QD updates RSS · CI watch RSS
Kuhnil Pharmaceutical Co., Ltd. portfolio CI